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Abstract. Background/Aim: Epidoxorubicin is an
anthracycline agent. The present study was undertaken to
compare the antileukemic potential of epidoxorubicin and its
two formamidine analogs containing either a morpholine
moiety (EPIFmor) or a hexamethyleneimine moiety
(EPIFhex) in the amidine group. Materials and Methods:
The experiments were performed in vitro on MOLT-4 cells
using spectrophotometry, Coulter electrical impedance, flow
cytometry, and light microscopy methods. Results: The
leukemia cell responses to the action of the anthracyclines
were manifested in their different viability, count and volume,
degree of apoptosis and necrosis, activity of caspases -8, -9,
and -3/7, mitochondrial membrane potential, and in the cell-
cycle distribution. In general, epidoxorubicin appeared to be
the most active, and EPIFmor was more active than EPIFhex
against MOLT-4 cells. Conclusion: The structural
modifications of epidoxorubicin in the amidine group were
responsible for the varied action of its formamidine analogs
on human acute lymphoblastic leukemia cells.
Anthracyclines are anticancer agents with broad clinical
implications. Nevertheless, anthracycline compounds still
have an improvable therapeutic index (1-3). The
development of new analogs is one of the strategies for
improving the efficacy of the parent anthracycline drugs used
in chemotherapy. Structural modifications of currently
approved anthracyclines are an important way to change
their anticancer activity (2, 4).
Epidoxorubicin (EPI) represents the second generation of
anthracycline compounds. Epidoxorubicin is a semisynthetic
derivative of doxorubicin obtained by an axial to equatorial
epimerization of the hydroxyl group at C-4’ in daunosamine
(1, 2, 4, 5). In search for new derivatives of anthracycline
agents, formamidine analogs of epidoxorubicin, containing
either a morpholine moiety (EPIFmor) or a hexamethyle-
neimine moiety (EPIFhex) in the amidine group, were
synthesized and their biological properties were tested under
in vitro conditions on different cell lines (6-9). However,
available information on anticancer potential of the synthesized
formamidinoepidoxorubicins (7-9), and especially their
antileukemic activity is still scant (8, 10).
Cell viability, size, and count (11, 12), cell death (13, 14),
and the cell cycle (15) are important parameters for
determining the antileukemic activity of potential anticancer
agents. Induction of cell death and changes in the cell cycle
by different chemical agents can affect the cell viability, size,
and count (13, 16). The alterations in these parameters
observed after application of tested compounds reflect their
cytotoxic activity (11-16). 
Regulated cell death plays a critical role in cellular
response to the action of various factors (17, 18). Apoptosis
and necrosis are accepted to be two principal modes of cell
death (19, 20). During cell death induced by different
cytotoxic agents, both functional and morphological changes
occur (19, 21-23). There are two main pathways, the
receptor/extrinsic and mitochondrial/intrinsic pathways, that
play a pivotal role in cells undergoing apoptotic and necrotic
death (20, 24, 25). These two pathways lead to activation of
caspases which are the important mediators of apoptotic cell
death (20, 26). The initiator caspase-8 and caspase-9 are
activated, respectively, through the receptor and
mitochondrial pathways. These initiator caspases activate
executor caspases (21, 27). It is accepted that mitochondria
have a central role in cellular homeostasis being the major
energy factory of cells (28), and apoptosis and necrosis are
generally determined as being energy-dependent cell death
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types (29, 30). Mitochondrial dysfunction can be reflected in
mitochondrial membrane permeability, the release of pro-
apoptotic factors, the formation of the apoptosome, which
activates caspase-9, and a decrease of mitochondrial
membrane potential (21, 31, 32). These changes in
mitochondria, as well as alterations triggered in the nucleus
and cell membrane by detrimental factors, can be involved
not only in different manifestations of cell death (33-35), but
also in cell-cycle perturbation (21, 32, 36). 
To our knowledge, there are no published data on the
effects of epidoxorubicin derivatives, containing a morpholine
ring or a hexamethyleneimine ring in the formamidine group,
on human acute leukemia cells. Elucidating and comparing the
modes of action of the parent anthracycline epidoxorubicin
and its analogs on malignant hematopoietic cells require
knowledge on their influence on the cell viability, regulated
cell death and the cell cycle. Therefore, the aim of the present
study was to assess the in vitro cytotoxic activity of
epidoxorubicin and the two analogs EPIFmor and EPIFhex
against human acute lymphoblastic leukemia cells. The
influence of these three anthracycline agents on cell viability,
count and size, apoptotic and necrotic cell death, and
alterations in the cell cycle was analyzed. In order to
determine the mechanisms of action of the tested
anthracyclines, the changes in plasma membrane structure and
integrity, caspase activation, mitochondrial membrane
potential, and the cell-cycle phase distribution, were evaluated.
Materials and Methods 
Chemicals. The anthracycline compounds, epidoxorubicin and its
two formamidine derivatives EPIFmor and EPIFhex, were
synthesized at the Institute of Biotechnology and Antibiotics
(Warsaw, Poland). The formamidinoepidoxorubicin compounds
were obtained in the reaction of epidoxorubicin hydrochloride with
acetals, derivatives of N-formylamines. The structure of the
formamidinoepidoxorubicins were confirmed by their 1H and 13C
nuclear magnetic resonance (NMR) spectra. Purity of all compounds
was ≥98.5% according to the HPLC methods (6). The anthracycline
agents, EPI, EPIFmor, and EPIFhex, were dissolved in aqua pro
injectione (Polpharma, Starogard Gdański, Poland). Stock solutions
of these three anthracycline agents, at a concentration of 0.5 mM,
were stored in the dark at −20˚C. All working solutions were freshly
prepared directly before treatment of cells (Figure 1).
RPMI-1640 medium, fetal calf serum, and Hank’s balanced salt
solution (HBSS) were obtained from Gibco BRL Life Technologies
(Waltham, MA, USA). L-glutamine, antibiotic antimycotic solution
(AAS), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT), tetramethylrhodamine ethyl ester perchlorate
(TMRE), and dimethyl sulfoxide (DMSO) were purchased from
Sigma Aldrich (St. Louis, MO, USA). Hydrochloric acid (HCl) and
absolute isopropanol from Krakchemia S.A. (Kraków, Poland),
formaldehyde from Polish Chemical Reagents, S.A. (Gliwice,
Poland), ISOTON II (filtered electrolyte solution based on 0.9%
saline) from Beckman Coulter Inc. (Brea, CA, USA), phosphate-
buffered saline (PBS) from BioMed (Lublin, Poland), and
Hemacolor staining set from Merck KGaA (Darmstadt, Germany)
were obtained. CaspGLOW Red Active Caspase-8 Staining Kit and
CaspGLOW Red Active Caspase-9 Staining Kit from Biovision
(Milpiats, CA, USA), and CellEvent™ Caspase-3/7 Green Flow
Cytometry Assay Kit from Molecular Probes (Eugene, OR, USA),
were purchased. Annexin V-FITC Apoptosis Detection Kit and
propidium iodide (PI)/RNase staining buffer were obtained from
Becton Dickinson Pharmingen™ (San Diego, CA, USA). 
Leukemia cells. Human acute lymphoblastic leukemia MOLT-4 cells
were obtained from the European Collection of Cell Cultures
(Salisbury, Wiltshire, UK). MOLT-4 cells were cultured in RPMI-1640
medium supplemented with 10% fetal calf serum, 2 mM L-glutamine,
and AAS containing 20 units of penicillin, 20 μg streptomycin and 50
ng amphotericin B. Every third day, MOLT-4 cells were passaged. The
leukemia cells grew at 37˚C in an atmosphere of 5% CO2 in air
(HERAcell incubator; KendroLab, Warsaw, Poland). 
Leukemia cell treatment with anthracyclines. After a dilution of the
cell suspension to a density of 15×104 cells/ml of complete RPMI-
1640 medium, MOLT-4 cells were treated with epidoxorubicin and
its two formamidine analogs. The concentrations of the
anthracyclines used in the experiments were based on the half
maximal inhibitory concentration (IC50) values determined using the
in vitro MTT assay. The control consisted of untreated MOLT-4
cells. The analyses were performed on the leukemia cells at 24/48
h after anthracycline application.
In vitro spectrophotometric MTT assay. In order to determine the
viability of MOLT-4 cells, an analysis of the optical density of
formazan solution was performed, according to the protocol
described in detail by Śladowska et al. (12). The IC50 value for each
anthracycline was determined separately in MOLT-4 cells at the
concentration range of EPI and EPIFmor from 10-100 nM, and
EPIFhex from 20-500 nM.
Cell sizing and counting – Coulter method. The leukemia cell
volume and count were analyzed as previously described by
Śladowska et al. (12). After the dilution of cell suspension in
ISOTON II (1:9), the count and volume of MOLT-4 cells were
determined to be in the range of 495-3622 fl.
Flow cytometric analysis of apoptotic and necrotic leukemia cells. The
cell surface exposure of phosphatidylserine and plasma membrane
impairment were assessed by dual staining of MOLT-4 cells with
annexin V-FITC and PI, using Annexin V-FITC Apoptosis Detection
Kit. Briefly, leukemia cell suspension containing approximately 5×105
cells was centrifuged for 7 min at 100 × g and 4˚C (MPW-351RH
centrifuge; Med. Instruments, Warszawa, Poland). Next, the cells were
washed with cold PBS. After centrifugation of the cell suspension, the
supernatant was removed, and the cells were resuspended in 100 μl of
cold binding buffer. Then 2.5 μl of annexin V-FITC and 2.5 μl of PI
were added and the cells were incubated in the dark for 15 min at
room temperature. Following incubation, 400 μl of cold binding buffer
was added. Cell samples were placed on ice, away from light, and
FITC and PI fluorescence was immediately measured, using a flow
cytometer (Becton Dickinson, San Jose, CA, USA). 
Microscopic analysis of leukemia cell morphology. In order to prepare
cytospins, leukemia cell suspension, eventually diluted in PBS,
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containing approximately 2×105 cells, was placed into 
a cytospin chamber and centrifuged for 6 min at 100 × g and 4˚C
(MPW-350R centrifuge; Med. Instruments, Warszawa, Poland). After
air drying, the prepared cytospins were fixed in methanol at room
temperature for 15 min. Immediately before staining, the cytospins with
the fixed cells were rinsed with PBS, and stained with the Hemacolor
staining set. The stained cytospins were examined using a light
microscope (PrimoStar; Carl Zeiss, Poznań, Poland). Morphological
analysis of apoptotic and necrotic MOLT-4 cells was performed. The
incidence of cells with apoptotic and necrotic features among 9,000
MOLT-4 cells (1,000 cells per slide × 3 slides) was determined. 
Flow cytometric analysis of caspase-8 and -9 activities. The
leukemia MOLT-4 cells with active caspase-8 and caspase-9 were
analyzed using, respectively, CaspGLOW Red Active Caspase-8
Staining Kit and CaspGLOW Red Active Caspase-9 Staining Kit.
Briefly, the cell suspension was centrifuged for 7 min at 100 × g
and 37˚C (MPW-351RH; Med. Instruments), and the supernatant
was removed by aspiration. The cell pellet was resuspended in 150
μl of PBS, and 0.5 μl of Red-IETD-fluoromethylketone or 0.5 μl of
Red-LEHD-fluoromethylketone was added into each sample, and
the cells were incubated for 1 h at 37˚C. Then the cells were
centrifuged, the supernatant was removed, and the cells were
washed twice in 500 μl of wash buffer. After the washing step, the
cells were resuspended in 300 μl of wash buffer and immediately
analyzed by flow cytometry (Becton Dickinson). 
Flow cytometric analysis of caspase-3/7 activity. Activity of
caspase-3/7 in leukemia MOLT-4 cells were analyzed using
CellEvent™ Caspase-3/7 Green Flow Cytometry Assay Kit. Briefly,
the cell suspension was centrifuged for 7 min at 100 × g and 37˚C
(MPW 351 RH; Med. Instruments) and the supernatant was
removed by aspiration. The cells were resuspended in 500 μl of
PBS. Then 0.5 μl of CellEvent™ Caspase-3/7 Green Detection
reagent was added to each sample and the cells were incubated for
30 min at 37˚C. After incubation, the leukemia cell samples were
immediately analyzed using flow cytometry (Becton Dickinson). 
Flow cytometric analysis of mitochondrial membrane potential
(MMP). TMRE assay was used to analyze the MMP. A TMRE
stock solution was prepared at a concentration of 10 mM in
DMSO and stored at −20˚C. The final concentration of TMRE
staining solution used was 100 nM. The leukemia cell suspensions,
containing approximately 2.5-5×105 cells/ml, were centrifuged for
7 min at 100 × g and 37˚C (MPW-351RH; Med. Instruments).
Then the cell pellet was washed twice in 1 ml of warm HBSS.
Next, the cells were resuspended in 100 μl of 100 nM TMRE, and
incubated at 37˚C in the darkness. After 20-min incubation, the
cells were washed with 1 ml of warm HBSS and centrifuged.
Finally, the supernatant was discarded, the cells were resuspended
in 500 μl of HBSS, and TMRE fluorescence was immediately
detected by flow cytometry (Becton Dickinson).
Flow cytometric analysis of the cell cycle. Using PI/RNase staining
buffer, the cell cycle distribution was analyzed. The leukemia cell
suspension was centrifuged for 7 min at 100 × g and 4˚C (MPW-
351 RH centrifuge; Med. Instruments) and the supernatant was
discarded. The cells were washed in 2 ml of cold PBS. The
supernatant was removed, the cell pellet was resuspended in 500 μl
of PBS, and 4.5 ml of 70% of ice-cold ethanol was added to the
sample. The cells were fixed in a refrigerator for 60 min, and then
stored at −20˚C before use. Before staining with PI, the leukemia
cell suspension was centrifuged, and the cell pellet was resuspended
in 1 ml of wash buffer. The cells were then centrifuged, the
supernatant was removed, and the cell pellet was resuspended in
300 μl of PI/RNase staining buffer. Next, the cells were incubated
in the darkness for 30 min at room temperature. After the
incubation, PI fluorescence was detected using flow cytometry
(Becton Dickinson). 
Statistical evaluation. The flow cytometric data were analyzed
using CellQuest Pro software (Becton Dickinson). All the data
are presented as the mean values±standard deviation, calculated
from three or four independent experiments carried out in
triplicate or duplicate. Statistical analyses were performed using
STATISTICA 10 (StatSoft, Krakow, Poland). Data were
analyzed by one-way analysis of variance (ANOVA) followed
by Tukey’s honestly significant differences (HSD) multiple
range test. A difference with p<0.05 was considered statistically
significant. 
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Figure 1. Chemical structures of epidoxorubicin (EPI) and its formamidine derivatives containing either a morpholine moiety (EPIFmor) or
a hexamethyleneimine moiety (EPIFhex) in the amidine group.
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Figure 2. Effects of epidoxorubicin (EPI), EPIFmor, and EPIFhex on the count and volume of MOLT-4 cells. The volume distribution curves of the
leukemia cells were recorded 24 (A) and 48 h (B) after their exposure to the action of the tested anthracyclines using a Z2 Coulter counter. The
peaks on the left represent cellular debris, presumably apoptotic bodies and cell fragments, which were excluded from the analysis of the MOLT-4
cell volume. The cell count (C) and the mean cell volume (D) were determined 24 and 48 h after application of EPI, EPIFmor, and EPIFhex, at
concentrations equal to or approximately the half-maximal inhibitory concentration values, calculated for each anthracycline agent, respectively,
as 30 nM (EPI30), 50 nM (EPIFmor50), and 200 nM (EPIFhex200). Values not significantly different at p<0.05 according to Tukey’s multiple range
test: #compared to control; *, **, ***between groups of leukemia cells treated with anthracyclines; +between time points.
Table I. The optical density of formazan solution and viability of MOLT-4 cells determined 48 h after their exposure to the action of epidoxorubicin
(EPI) and its formamidine derivatives, EPIFmor and EPIFhex, using the spectrophotometric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) assay. The extent of MTT conversion to formazan by leukemia cells expressed as a percentage of the control value reflects their viability.
                                                        Optical density of formazan solution (×10–2)                                                    Cell viability (%)
Concentration (nM)                    EPI                            EPIFmor                    EPIFhex                       EPI                          EPIFmor                      EPIFhex
10                                          12.6±0.3                        13.5±0.2                           -                         86.3±2.0                      92.5±1.4                             -
20                                           9.5±0.3                         12.8±0.2                    14.2±0.2                   65.1±2.0                      87.7±1.4                      97.3±1.4
30                                           7.2±0.8                         11.3±0.3                           -                         49.3±5.5                      77.4±2.1                             -
40                                           1.8±0.1                               -                                 -                         12.3±0.7                            -                                   -
50                                           1.5±0.3                          7.3±0.9                     13.2±0.7                   10.3±2.1                      50.0±6.2                      90.4±4.5
70                                                 -                               5.1±0.2                            -                                -                            34.9±1.4                             -
80                                                 -                               3.4±0.8                            -                                -                            23.3±5.5                             -
100                                           1.1±0.2                          2.5±0.3                     11.8±1.5                    7.5±1.4                       17.1±2.1                     80.8±10.3
200                                                 -                                     -                            7.4±0.5                          -                                   -                             50.7±3.4
300                                                 -                                     -                            3.6±0.2                          -                                   -                             24.6±1.4
500                                                 -                                     -                            1.8±0.3                          -                                   -                             12.3±2.1
Control          14.6±0.9                                                                                                                                                              
- Not done. Bold data correspond to the concentrations equal or similar to the half-maximal inhibitory concentration (IC50) values. The IC50 value
for EPIFmor was determined as 50 nM.
Results
The results of the present study demonstrated that
epidoxorubicin and its formamidine analogs reduced MOLT-4
cell viability. Based on the optical density of formazan solution
obtained 48 h after application of the anthracyclines (Table I),
the IC50 values for EPI, EPIFmor, and EPIFhex were
determined from the dose–response curves, as 30.4 nM, 50.0
nM, and 197.3 nM, respectively. The anthracyclines, applied at
the concentrations similar or equal to the IC50 values,
influenced the count (Figure 2A-C) and volume (Figure 2A, B,
and D) of MOLT-4 cells to different extents. The exposure of
leukemia cells to the action of the anthracycline agents, at the
concentration of 50 nM, differently affected the frequency of
both annexin V-FITC+/PI− cells (Figure 3A-C) and annexin V-
FITC+/PI+ cells (Figure 3A, B, and D), cell morphology
(Figure 4A), the apoptotic (Figure 4B) and necrotic (Figure 4C)
index, the frequency of cells with active caspase-8 (Figure 5B),
-9 (Figure 5C), and -3/7 (Figure 5A and D), the percentage of
cells with high MMP (Figure 6A and B), the distribution of the
cell-cycle phases and sub-G1 population (Figure 7A and B),
excluding the influence of EPIFhex on caspase-8 activation
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Figure 3. Effects of epidoxorubicin (EPI), EPIFmor, and EPIFhex, applied at 50 nM, on the plasma membrane structure and integrity of MOLT-4
cells. Representative dot plots of MOLT-4 cells obtained 24 h (A) and 48 h (B) after application of the anthracyclines, using flow cytometry
fluorescein-conjugated annexin V (annexin V-FITC)/propidium iodide (PI) assay; FL1-H: green fluorescence of FITC, FL2-H: red fluorescence of
PI; R1: live cells (annexin V-FITC−/PI−) R2: early apoptotic cells (annexin V-FITC+/PI−); R3: late apoptotic and necrotic cells (annexin V-
FITC+/PI+). The frequency of early apoptotic (C) and late apoptotic and necrotic (D) MOLT-4 cells was determined 24 and 48 h after their exposure
to the action of the tested anthracyclines. +Values not significantly different between time points at p<0.05 according to Tukey’s multiple range test.
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Figure 4. Morphological analysis of MOLT-4 cells undergoing apoptotic and necrotic cell death was performed 48 h after application of
epidoxorubicin (EPI), EPIFmor, and EPIFhex, at 50 nM. A: Representative micrographs of MOLT-4 cells stained with the Hemacolor staining set,
and observed under a light microscope; original magnification ×1,000. Swollen necrotic cells, exhibiting morphological disintegration and
membrane rupture are visible after application of EPI and EPIFmor, and one shrunk apoptotic cell with nuclear fragmentation is visible after the
exposure of MOLT-4 cells to EPIFhex. After application of the tested anthracyclines, the frequency of apoptotic (B) and necrotic (C) cells was
determined. All values differed significantly at p<0.05 according to Tukey’s multiple range test. 
Figure 5. Flow cytometric analysis of MOLT-4 cells with active caspase-8, -9, and -3/7, conducted 24 h after application of epidoxorubicin (EPI),
and its two formamidine analogs, EPIFmor and EPIFhex, at 50 nM. A: Representative histograms of MOLT-4 cells with active caspase-3/7; 
M1: Cells with active caspase-3/7; FL1-H: CellEvent™ Caspase-3/7 Green fluorescence. The frequency of MOLT-4 cells with active caspase-8 (B),
caspase-9 (C), and caspase-3/7 (D) was determined after application of the tested anthracycline agents. #Values not significantly different compared
to controls at p<0.05 according to Tukey’s multiple range test.
(Figure 5B), MMP dissipation (Figure 6A and B), and the cell
cycle (Figure 7A and B). Thus, it can generally be stated that
among the three anthracyclines, epidoxorubicin had the
strongest activity and EPIFhex had the weakest activity against
human leukemia MOLT-4 cells. 
Discussion
The in vitro cytotoxic effects of epidoxorubicin and its two
formamidine derivatives, EPIFmor and EPIFhex, on human
acute lymphoblastic leukemia MOLT-4 cells were compared.
After application of these anthracyclines, MOLT-4 cells
exhibited different patterns of changes in their viability,
count and volume, extent of apoptotic and necrotic death,
phosphatidylserine externalization and plasma membrane
integrity, activity of caspases-8, -9, and -3/7, mitochondrial
membrane potential, and the cell cycle. Based on the IC50
values determined for EPI, EPIFmor and EPIFhex, the mode
of action of each of these anthracyclines resulted in different
viability of MOLT-4 cells. It can be accepted that the
disorders of regulated cell death and cell-cycle disruption
reflect leukemia cell viability. Moreover, the alterations
observed in the leukemia cell count and volume surely
resulted from the induction of cell death and cell-cycle
disturbance by epidoxorubicin and its analogs.
The results of the present study indicate that the cytotoxic
activities of two formamidinoepidoxorubicins, EPIFmor and
EPIFhex, were weaker than that of the parental epidoxorubicin.
Moreover, among these analogs of epidoxorubicin, EPIFmor,
containing a morpholine moiety appeared to be more active
against MOLT-4 cells than EPIFhex, containing a
hexamethyleneimine moiety in the amidine group. Therefore,
the transformation of the amino group at position 3’ of the
daunosamine moiety into a formamidine group (-N=CH-N<)
resulted in analogs with different cytotoxic action compared to
that of epidoxorubicin. EPIFmor and EPIFhex differ in the size
of the cyclic amine ring in the amidine group (6). EPIFmor
contains a six-membered morpholine ring with an oxygen
heteroatom, while EPIFhex has a seven-membered
hexamethyleneimine ring with a CH2 group in the γ-position
in the formamidine group. The differences in the molecular
structure of these two formamidine derivatives of
epidoxorubicin appeared to be responsible for their different
biological action on human acute lymphoblastic leukemia cells.
The present study provides new insight into the
mechanisms of cytotoxic action of epidoxorubicin and its
formamidine analogs towards MOLT-4 cells. It was found
that epidoxorubicin and the formamidinoepidoxorubicins,
when applied at the same concentration of 50 nM, caused
plasma membrane impairment and loss of its phospholipid
asymmetry by phosphatidylserine externalization, nuclear
damage and mitochondrial dysfunction, and promoted the
activation of caspases through the mitochondrial pathway of
apoptotic death. However, only epidoxorubicin and EPIFmor
reduced MMP, activated caspases through the receptor
pathway, and affected the cell-cycle phase distribution in
MOLT-4 cells. In the present study, the different mechanisms
of action of epidoxorubicin, EPIFmor, and EPIFhex on
human leukemia MOLT-4 cells, which include triggering
apoptotic and necrotic death and causing the cell-cycle
perturbation, were shown. 
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Figure 6. Effects of epidoxorubicin (EPI) and its formamidine
derivatives, EPIFmor and EPIFhex, applied at 50 nM, on mitochondrial
membrane potential (MMP) of MOLT-4 cells. A: Representative dot
plots of MOLT-4 cells obtained 24 h after their exposure to the action
of three anthracyclines, using flow cytometric tetramethylrhodamine
ethyl ester test; R1: cells with high MMP, R2: cells with low MMP. B:
The frequency of MOLT-4 cells with high MMP was determined 24 h
and 48 h after application of the tested anthracycline agents. Values not
significantly different at p<0.05 according to Tukey’s multiple range
test: #compared to controls; +between time points.
Multiple mechanisms have been proposed to explain the
cytotoxic actions of anthracyclines (2, 4, 37). It is known that
epidoxorubicin generates free radicals with consequent
interference with DNA, RNA, and proteins. Epidoxorubicin
acts by intercalating of DNA strands, triggering DNA cleavage
by topoisomerase II, which result in the inhibition of DNA and
RNA synthesis (2, 4). Nevertheless, the modes of biological
action of anthracyclines, including EPI, and especially their
formamidine analogs, and the precise mechanisms responsible
for the in vitro cytotoxic effects caused by these agents are not
yet completely explained (2, 4, 37). 
Conclusion 
The findings of the present study indicate that differences in
the in vitro antileukemic activities of epidoxorubicin and its
formamidine derivatives depend on their chemical structures.
The structural modifications of the daunosamine moiety of
epidoxorubicin were reflected in the varied responses of
human acute lymphoblastic leukemia MOLT-4 cells to the
triggering apoptotic and necrotic death and the cell-cycle
disturbance by EPIFmor and EPIFhex. Understanding the
mechanisms of action of formamidinoepidoxorubicin agents
is essential for the development of novel therapeutic
strategies. The relationship between the induction of
regulated cell death and cell-cycle inhibition, and the
efficacy of chemotherapy is still an open issue.
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